Analysis of factors associated with sterile inflammation in women with pe receiving different antihypertensive treatment strategies

Systemic inflammation alongside endothelial dysfunction is considered to play a crucial role in PE pathogenesis. Endothelial dysfunction can be assessed by endothelial glycocalyx (eGC) damage. eGC is a superficial layer of cells associated with endothelial membrane that provides all endothelial cells functions. Its damage can be evaluated by the levels of its circulating components in blood. Patients with PE generally receive methyldopa (Dopegyt) solely or in combination with nifedipine (Cordaflex), and there is no understanding of their effect on proinflammatory state of blood vessels. Our study aimed to assess levels of IL-6, IL-18, TNFα, galektin-3 and homocysteine as well as levels of syndecan-1, eCG structural component, representing system inflammatory response and endothelial dysfunction development in blood of women with early- and late-onset PE receiving different antihypertensive treatment strategies. Eighty-two patients were enrolled into this interventional longitudinal pilot study. The comparison group included 15 patients before 34 gestational weeks and 15 patients after 34 weeks. Study subgroup 1 included 12 patients with early- onset PE receiving Dopegyt solely and 16 patients with early-onset PE receiving Dopegyt together with Cordaflex. Study subgroup 2 included 12 patients with late-onset PE receiving Dopegyt solely and 12 patients with late-onset PE receiving combined therapy. As for early-onset PE, only IL-6 demonstrated statistically significant differences in patients receiving both treatment strategies compared to control. Proinflammatory state was more profound in late-onset PE. IL-6 levels were significantly increased in late-onset PE treated with Dopegyt. IL-6 and TNFa levels were significantly higher in late-onset PE patients treated with Dopegyt + Cordaflex compared to control. Syndecan-1 levels were statistically significantly higher in patients with early-onset PE treated with Dopegyt solely. There were no statistically significant differences between the groups despite elevated mean values of syndecan-1 in late-onset PE. Galectin-3 and homocysteine levels did not differ significantly between the groups, representing lack of pronounced inflammatory response and endothelial dysfunction.

1. Banerjee S., Huang Z., Wang Z., Nakashima A., Saito S., Sharma S., Cheng S. Etiological value of sterile inflammation in preeclampsia: is it a non-infectious pregnancy complication? Front. Cell. Infect. Microbiol., 2021, Vol. 11, 694298. doi: 10.3389/fcimb.2021.694298.

2. Chaulin A.M., Grigorieva Yu.V. Galectin-3 as a prognostin biomarker of heart failure. International Research Journal, 2021, Vol. 104, no. 2, pp. 55-60.

3. Cox L.S., Redman C. The role of cellular senescence in ageing of the placenta. Placenta, 2017, Vol. 52, pp. 139-145.

4. Dronova T.A., Polyakov D.V. Clinical efficiency and influence of combined antihypertensive yherapy upon cytokine profile in the patients with arterial hypertension. Medical Immunology (Russia), 2009, Vol. 11, no. 1, pp. 49¬56. (In Russ.) doi: 10.15789/1563-0625-2009-1-49-56.

5. Elsherbiny N.M., Sharma I., Kira D., Alhusban S., Samra Y.A., Jadeja R., Martin P., Al-Shabrawey M., Tawfik A. Homocysteine induces inflammation in retina and brain. Biomolecules, 2020, Vol. 10, no. 3, 393. doi: 10.3390/biom10030393.

6. Huang X., Huang H., Dong M., Yao Q., Wang H. Serum and placental interleukin-18 are elevated in preeclampsia. J. Reprod. Immunol., 2005, Vol. 65, no. 1, pp. 77-87.

7. Lau S.Y., Guild S.J., Barrett C.J., Chen Q., McCowan L., Jordan V., Chamley L.W. Tumor necrosis factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a systematic review and meta-analysis. Am. J. Reprod. Immunol., 2013, Vol. 70, no. 5, pp. 412-427.

8. Muminova K.T., Ziganshina M.M., Khodzhaeva Z.S. Evaluation of the effect of different strategies of antihypertensive treatment on endothelial glycocalyx in patients with preeclampsia. Exp. Clin. Pharm., 2022, Vol. 85, no. 10, pp. 4-10.

9. Pankiewicz K., Szczerba E., Fijalkowska A., Szamotulska K., Szewczyk G., Issat T., Maciejewski T.M. The association between serum galectin-3 level and its placental production in patients with preeclampsia. J. Physiol. Pharmacol., 2020, Vol. 71, no. 6. doi: 10.26402/jpp.2020.6.08.

10. Pinheiro M.B., Gomes K.B., Ronda C.R., Guimaraes G.G., Freitas L.G., Teixeira-Carvalho A., Martins- Filho O.A., Dusse L.M. Severe preeclampsia: association of genes polymorphisms and maternal cytokines production in Brazilian population. Cytokine, 2015, Vol. 71, no. 2, pp. 232-237.

11. Preeclampsia. Eclampsia. Edema, proteinuria and hypertensive disorders during pregnancy, childbirth and the postpartum period, Clinical guidelines (approved by the Ministry of Health of the Russian Federation). 2021, 54 p. Available at: http://disuria.ru/_ld/10/1046_kr21O10O16MZ.pdf.

12. Redman C.W., Sargent I.L. Placental stress and pre-eclampsia: a revised view. Placenta, 2009, Vol. 30, Suppl A, pp. S38-S42.

13. Xu B., Thornton C., Makris A., Ogle R., Hennessy A. Anti-hypertensive drugs alter cytokine production from preeclamptic placentas and peripheral blood mononuclear cells. Hypertens. Pregnancy, 2007, Vol. 26, no. 3, pp. 343-356.

14. Ziganshina M.M., Pavlovich S.V. New approaches to the prevention and treatment of arterial hypertension fron the standpoint of pharmacological correction of endothelial glycocalyx: experimental and clinical data. Exp. Clin. Pharm., 2021, Vol. 84, no. 7, pp. 26-36.

15. Ziganshina M.M., Yarotskaya E.L., Bovin N.V., Pavlovich S.V., Sukhikh G.T. Can endothelial glycocalyx be a major morphological substrate in pre-eclampsia? Int. J. Mol. Sci., 2020, Vol. 21, no. 9, 3048. doi: 10.3390/ijms21093048.

16. Ziganshina M.M., Ziganshin A.R., Khalturina E.O., Baranov I.I. Arterial hypertension as a consequence of endothelial glycocalyx dysfunction: a modern view of the problem of cardiovascular diseases. Cardiovasc. Ther. Prev., 2022, Vol. 21, no. 9, 3316. doi: 10.15829/1728-8800-2022-3316.